Adverse events should be reported. Reporting form and information can be found at www.hpra.ie. Adverse events should also be reported to the Ipsen Medical Information Department on +353 18098256 or pharmacovigilance.uk-ie@ipsen.com
Access using the code provided
The information on this website is intended only to support patients prescribed Cabometyx® (cabozantinib) for advanced renal cell carcinoma (aRCC) and is not intended for the general public.
It is designed for patients in Ireland and should not replace the opinion provided by your healthcare professional or the details contained in the Patient Information Leaflet.
By entering this website, you are confirming you are a patient who has been prescribed Cabometyx®.
Please contact your healthcare team if you no longer have your access code.
Access using the code provided
The information on this website is intended only for healthcare professionals in the Republic of Ireland prescribing Cabometyx® (cabozantinib) for advanced renal cell carcinoma (aRCC) and is not intended for the general public.
This website is for promotional purposes only and should not replace the details contained in the Patient Information Leaflet and/or the SmPC (Summary of Product Characteristics).
By entering this website, you are confirming you are a healthcare professional prescribing Cabometyx® in the Republic of Ireland.
Please contact your local Ipsen representative if you no longer have your access code.
You are now leaving the Cabometyx® Ireland website and will be re-directed to www.ipsen.com/uk-ireland/our-medicines